Literature DB >> 20345338

Peg-asparaginase for acute lymphoblastic leukemia.

Michael Rytting1.   

Abstract

IMPORTANCE OF THE FIELD: Asparaginase is a prominent component of pediatric and adolescent treatment for acute lymphoblastic leukemia. These treatment regimens are now being employed in adults. Knowledge of the efficacy and toxicity of asparaginase preparations is essential when using these treatments. AREAS COVERED BY THIS REVIEW: The search terms used were asparaginase, leukemia, pegylated, oncaspar, adolescent and young adult. Literature was searched in Pubmed/Medline with no limitations on year of publication. Abstracts from the American Society of Hematology meetings and the American Society of Clinical Oncology were searched from 2004 - 2008 using the same terms. WHAT THE READER WILL GAIN: The reader will gain knowledge of the tolerability and efficacy of pegylated asparaginase when treating acute lymphoblastic leukemia. TAKE HOME MESSAGE: Pegylated asparaginase is generally well tolerated in adult patients with efficacy that appears to be at least equivalent to native asparaginase preparations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20345338     DOI: 10.1517/14712591003769808

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  20 in total

1.  Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Tapan M Kadia; Hagop M Kantarjian; Deborah A Thomas; Susan O'Brien; Zeev Estrov; Farhad Ravandi; Elias Jabbour; Naveen Pemmaraju; Naval Daver; Xuemei Wang; Preetesh Jain; Sherry Pierce; Mark Brandt; Guillermo Garcia-Manero; Jorge Cortes; Gautam Borthakur
Journal:  Am J Hematol       Date:  2014-11-19       Impact factor: 10.047

2.  Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial.

Authors:  Jonathan I Sive; Georgina Buck; Adele Fielding; Hillard M Lazarus; Mark R Litzow; Selina Luger; David I Marks; Andrew McMillan; Anthony V Moorman; Susan M Richards; Jacob M Rowe; Martin S Tallman; Anthony H Goldstone
Journal:  Br J Haematol       Date:  2012-03-13       Impact factor: 6.998

3.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift.

Authors:  Jason R Cantor; Tae Hyeon Yoo; Aakanksha Dixit; Brent L Iverson; Thomas G Forsthuber; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-05       Impact factor: 11.205

4.  High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase.

Authors:  Katja M J Heitink-Pollé; Berthil H C M T Prinsen; Tom J de Koning; Peter M van Hasselt; Marc B Bierings
Journal:  JIMD Rep       Date:  2012-07-01

Review 5.  Treatment of acute lymphoblastic leukemia in adolescents and young adults.

Authors:  Joseph M Brandwein
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

6.  Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.

Authors:  Lesleigh S Abbott; Maria Zakova; Furqan Shaikh; Nisha Shewaramani; Angela Punnett; L Lee Dupuis
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

7.  Serum amino acid levels as a biomarker for renal cell carcinoma.

Authors:  Aladdin Mustafa; Sapna Gupta; Gary R Hudes; Brian L Egleston; Robert G Uzzo; Warren D Kruger
Journal:  J Urol       Date:  2011-08-17       Impact factor: 7.450

Review 8.  Cancer cell metabolism: one hallmark, many faces.

Authors:  Jason R Cantor; David M Sabatini
Journal:  Cancer Discov       Date:  2012-09-25       Impact factor: 39.397

9.  Treatment of children with advanced-stage lymphoblastic lymphoma with pegaspargase.

Authors:  Zhang Yu-Tong; Feng Li-Hua; Zhong Xiao-Dan; Wang Li-Zhe; Chang Jian
Journal:  Iran J Pediatr       Date:  2014-01-26       Impact factor: 0.364

Review 10.  Novel agents and biomarkers for acute lymphoid leukemia.

Authors:  Yanmin Zhao; He Huang; Guoqing Wei
Journal:  J Hematol Oncol       Date:  2013-06-18       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.